Two Stock Picks for the Cold and Flu Season

Written by admin on May 6th, 2011

In this article, discusses two stock picks for the 2008 – 2009 cold and flu season: MTXX and RAD. discusses two stock picks for this cold and flu season. has picked hundreds of stock picks in the past and regularly comments on stock picks, penny stocks, hot stocks and small cap stocks on and in their stock newsletter. Now, is the time to be looking at stocks again, particularly the cold and flu sector as the stock market begins to find a market bottom and investors research key, timely sectors. MTXX is the developer and marketer of the Zicam cold and flu remedy brand with a distribution network that includes Wal-Mart, Walgreens, and CVS.’s second stock pick for the cold and flu season, RAD (Rite Aid), a drugstore retail chain with prescription and over-the-counter medication for cold and flu and other ailments. Stock Pick: Matrixx Initiatives, Inc. (MTXX) Stock Price: .77 Matrixx Initiatives, Inc. is engaged in the development and marketing of over-the-counter healthcare products that utilize the company’s drug delivery systems. Its wholly-owned subsidiary, Zicam, LLC, markets and sells ZicamĀ® and Nasal Comfort(TM) products in the cough and cold category. MTXX also offers Zicam Multi-Symptom Cold and Flu Relief products, which utilize a spoon dosing delivery to provide relief of cold and flu symptoms. MTXX is a perennial cold and flu season stock play and well known for that fact. MTXX dropped the last four trading days creating a buying opportunity to play this year’s cold and flu season. MTXX’s over-the-counter cold and flu products are sold at several large national retailers including Wal-Mart, Walgreens, and CVS. Zicam is one of the top three cough, cold and allergy growth brands and its multi-symptom cold and flu products account for 45% of the company’s retail sales growth. MTXX has an attractive brand and sold distribution network in place. We believe MTXX will have another cold and flu season move. Stock Pick: Rite Aid Corporation (RAD) Stock Price: .31 Rite Aid Corporation is a drugstore chain with more than 4,900 stores in 31 states and the District of Columbia. The company’s fiscal 2008 annual sales totaled more than .3 billion. Rite Aid is a major brand that continues to expand. Patients fill their prescriptions at Rite Aid for various ailments and shop for over-the-counter medication for cold and flu and other illnesses. RAD has been down significantly this year, but we see the potential for a major turn around in the future for RAD. Three independent proxy advisory firms have recommended RAD stockholders support RAD’s Board of Directors’ plan for a reverse split. The reverse stock split could be approved on December 2nd. Reverse stock split is never a good phrase to investors, but in this case it looks like it must be done and we believe most of the negativity is already priced into RAD. After the reverse split, we expect investors to look at RAD in a new, refreshing light. We believe RAD will receive major attention as a cold and flu season play over the next 1 – 2 months. Also, we expect RAD to begin its turn around. At, we believe it is important to find the right small cap stocks and penny stocks at the right time in their stock chart and business cycle. With MTXX and RAD, we believe we have found two stocks that have a great chance at becoming hot stocks in the short-term. About releases penny stocks, penny stock picks, small cap stock picks and discusses hot stocks in the stock market on a daily basis. We are focused on value stocks and finding the best stocks and investment opportunities. We provide a market update each day on market trends and scour the market for undervalued stocks and growth stocks to release to our stock membership group and stock market newsletter. We use our proprietary stock research for choosing our stock picks. also discusses pink sheets and OTCBB stocks. For more stock information, go to for day trading alerts, momentum stocks and stock market articles. Join our stock newsletter. This article is the opinion of, Inc., Inc. is not a registered investment advisor and nothing contained in any materials released by us should be construed as a recommendation to buy or sell any securities. Please read our legal disclaimer at

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Leave a Reply